Rebecca Simmons COO

52North (Cambridge, UK) is a medical technology company on a mission to make urgent care pathways safer and more effective. Awarded breakthrough status for its first product Neutrocheck® by the UK Government in 2024, 52North builds innovative diagnostic and digital solutions to transform patient journeys in urgent care. Its award-winning, multidisciplinary team is based in Cambridge, UK. 52North is backed by leading UK and US hospital venture funds, Meridian Health Ventures and Cedars-Sinai Intellectual Property company.

Therapeutic: Oncology; Digital Health

Daniela Schardinger Marketing Manager

Ark Surgical (Israel, Nazareth) is a women’s health medtech company redefining safety in laparoscopic and robotic gynecologic surgery.

Its FDA-cleared LapBox® prevents tissue spillage during manual and power morcellation — addressing a new market created by an FDA safety mandate.

Already in use at leading U.S. hospitals, LapBox® delivers superior containment, clear visualization, and compatibility with robotic platforms.

Targets 650K annual U.S. uterine surgeries and 1.5M+ globally, a $260M+ U.S. market at a $400 ASP.

With the robotic surgery market growing from $9.6B (2023) to $23.7B (2029, 16.5% CAGR), Ark is a first mover in a high-growth, regulator-driven space.

Positioned to lead a multi-billion–dollar opportunity in women’s health and surgical safety.

Therapeutic: Gynecology / Minimally Invasive Surgery (MIS) — specifically for procedures such as laparoscopic hysterectomy, myomectomy, and adnexal mass removal.

Daniel Gelman CEO

Aufero Medical (London, Ontario, Canada) is transforming cardiac ablation with TruContact, a robotic tool enhancing catheter stability during ablation therapy for atrial fibrillation and heart rhythm disorders. Unstable catheters, an issue in half of procedures, reduce success rates. TruContact uses robotics and machine learning to ensure catheter stability, delivering high-quality ablations and empowering physicians of all skill levels. Partnered with leading EP market players, Aufero has raised over $1M, generated robust preclinical data, and secured strategic partnerships for global market expansion.

Therapeutic: Cardiovascular & Electrophysiology

Randy Pritchard CEO

Axena Health (Auburndale, MA, USA) is a commercial-stage medical device company dedicated to improving the lives of women through clinically proven non-surgical treatments for pelvic floor disorders.  Axena Health’s product, the Leva® Pelvic Health System, offers a novel, clinically proven, at-home treatment for urinary incontinence (UI) and chronic fecal incontinence (FI), conditions that currently lack effective, scalable non-surgical treatment options.  The Leva System has multiple clinical trials and published data from globally recognized medical centers supporting its efficacy in treating UI, including two studies published in Obstetrics and Gynecology (The Green Journal), the official publication of the American College of Obstetricians and Gynecologists (ACOG). 

Therapeutic: Women’s Health

Enrique Vega CEO

Azalea Vision (Ghent, Belgium) is a health-tech company developing the first intelligent, lens-embedded system that senses, adapts, and connects in real time to improve vision and monitor eye health. Our lens integrates adaptive optics, microelectronics, and connectivity. It senses visual changes and adjusts in real time—restoring clear vision without surgery. 

Our first product is for patients suffering from corneal irregularities such as keratoconus and presbyopia—conditions that cause blurred or distorted vision. The next platform is designed to measure biomarkers like glucose, lactate, pH, sodium, and potassium, enabling future applications in health monitoring and sports performance tracking.

 Azalea has begun gathering clinical data, the first milestone in their clinical program that will secure EU and U.S. market access.

Therapeutic: Medical devices, Ophthalmic devices, Smart Contact Lens

John Brumfield CEO

With the C-MIC Device - Berlin Heals (Zug, Switzerland) has developed an innovative, disruptive and easily implantable low-invasive microcurrent therapeutic device that has demonstrated tremendous clinical effects never seen before in heart failure patients.

Therapeutic: Cardiovascular; Heart Failure

Ilan Uchitel CEO

CAPS Medical (Israel) has developed a proprietary PlasmaSure technology that uses Non Thermal Plasma (NTAP) to selectively target tumors through minimally invasive procedures. The PlasmaSure system uses existing minimally invasive tools and robotic systems, targeting a $100B TAM. CAPS effectively eliminates cancerous cells while preserving healthy tissue, allowing treatments to move from the operating room into a doctor's clinic. The technology is clinically tested and applicable to wide range of tumors.

Therapeutic: Oncology

Jason Topolosky CEO

EXG by CB Innovations (Carlsbad, CA) is a proprietary continuous diagnostic wearable 3L, 4l, 5L, and 12L FDA registered platform designed to standardize AHA-compliant accurate lead placement resulting in cleaner, higher-quality ECG tracings and faster clinical decision-making, leading to prompt treatment and timely transfer decisions.

Therapeutic: Cardiac

Jason Mowles CEO

CergenX (Cork, Ireland) is an AI-driven neurotechnology company redefining how early brain health is assessed. Built on decades of groundbreaking neonatal brain research, its proprietary AI platform transforms complex physiological data into real-time, expert-level insights and accelerates the development of high-impact clinical solutions. The company’s first product, Wave, is an FDA-designated breakthrough device that identifies newborns at highest risk of brain injury. Delivering expert-informed brain function assessments at the point of care in under 15 minutes, Wave supports timely intervention and improved outcomes.

Therapeutic: Artificial Intelligence; Neonatal Neurology

Cody Simmons Co-Founder & CEO

DermaSensor Inc. is a Miami-based medical device company that enables healthcare professionals to effectively check for skin cancer by leveraging cutting-edge technologies. The DermaSensor™ solution is a cost-effective handheld device that combines artificial intelligence and spectroscopy to non-invasively test skin lesions for skin cancer risk in seconds. This FDA Breakthrough and De Novo cleared device is the only automated skin cancer detection tool of any kind available to PCPs. By enabling immediate results at the point of care, DermaSensor has already empowered hundreds of healthcare providers in the US with a clinically proven solution for early skin cancer detection. 

Therapeutic: Dermatology; Oncology

Jake Edick CEO and Co-Founder

Entirety Biomedical (East Lansing, MI, USA) is redefining orthopedic fixation options with its patented Curasorb absorbable metal technology. Curasorb implant systems combine titanium-like strength with optimized absorption to heal fractures, restore bone to natural physiology, and eliminate the long-term complications, costs and trauma caused by traditional permanent implants. With superior outcomes and streamlined patient recovery, Curasorb creates a new and improved standard for fixation surgery care and patient wellbeing.

Therapeutic: Biomaterials; Orthopedics- Initial Product Launches

David Constantine Co-Founder & CEO

Juniper Biomedical is developing the future of precision bioelectronic medicine with a unique neuromodulation micro-implant to provide dramatically improved treatments for pelvic health conditions like urinary or fecal incontinence, sexual dysfunction and chronic pelvic pain for both women and men. Our first application is the treatment of Mixed Urinary Incontinence (estimated at 2/3 of the 78M women with urinary incontinence in the US alone), with one implant, half the size of a US dime. Our long term implant delivers automatic therapy for symptoms of both urge and stress incontinence (both components of mixed) with a pipeline of pelvic health applications behind it. Juniper was one of the two winners of the NIH SPARC Neuromod Prize (all three phases) and a 2024 Finalist in MedTech Innovator.

Therapeutic category: Neuromodulation/Bioelectronic Medicin, Pelvic Health

Dom Messerli President & CEO

Based in Providence, Rhode Island, Lenoss Medical is a medical device company dedicated to the design, development and commercialization of a novel biological implant and associated delivery instrumentation for the treatment of painful vertebral compression fractures. Lenoss Medical developed the only fully biological solution for treating VCFs. The OsteoPearl Biological Augmentation is a minimally invasive spinal implant designed to stabilize the spinal fracture and create an environment for restoration and healing. Immediate stability is created by the structural matrix, introducing both osteoinductive and osteoconductive properties. Placing Natural bone where More bone is needed most.

Therapeutic: Pain management; Orthopedics-Spine

Patrick O’Donnell President & CEO

The company (Woburn, MA USA) is advancing spinal fusion through bioactive intelligent technology. A rapid growth, commercial stage company, NanoHive’s proprietary, biomimetic Soft Titanium® technology clearly distinguishes their products in the spinal interbody fusion device market. The company is embarking upon the development of breakthrough sensor-embedded and patient-specific implant technologies that harness the clinical success of their core technology. The Hive™ portfolio of interbody fusion devices provide surgeons and their patients ideal biomechanical elastic modulus properties, clear and precise diagnostic imaging capability, osteoblast cell attraction and integration – all features that lead to consistently strong fusion constructs and efficacious clinical experiences.

Therapeutic: Orthopedics-Spine

Xiaopei Huang CEO

We are a medical device company developing next-generation SPECT imaging systems with unmatched sensitivity and accuracy. Our technology is designed to advance radiopharmaceutical development and molecular imaging for clinical use, enabling faster, higher-resolution scans with improved quantification. By addressing limitations of current imaging systems, we aim to support the growing needs of clinicians and researchers in neurology, oncology, and theranostics. Our mission is to accelerate drug development and improve patient outcomes through innovative molecular imaging solutions.

Therapeutic: Diagnostics

Esther Novosel CEO

Neuroloop (Freiburg, Germany) will develop & market a technology platform based on thin-film technology for controllable selective stimulation of the vagus nerve. Our Agenda is driven by 3 Key projects: 1. baroloop®: VNS stimulation to lower Blood pressure in patients with true resistant Hypertension. 2. VNS stimulation to address an anti-inflammatory indication (in cooperation with Merck KGaA) 3. Continuous platform development: closed loop, new sensors, remote monitoring & programming. For baroloop we are currently running a multi-center approval trial for CE market.

Therapeutic: Neuromodulation-neurostimulation; Hypertension

Lloyd Diamond CEO

EndoZip, World’s First Automated Endoscopic Treatment for Obesity from Nitinotes Surgical (Ceasarea, Israel).

Therapeutic: Obesity

Ze'ev Dvashi CEO

ClearPlasma (Nazareth, Israel) is a groundbreaking blood filtration device that removes plasminogen from plasma prior to transfusion—offering a novel, clinically validated solution to improve clot stability, reduce bleeding, and save lives in trauma, surgery, and critical care settings.

Therapeutic: Emergency care to treat massive blood loss

James Bowman CEO

PURGO Surgical (Salt Lake CIty, Utah, USA) has developed an FDA Breakthrough Device designated product platform for targeted localized drug delivery to solve the drawbacks of systemic drug delivery in multiple clinical indications. It has proven success in treating infections and has great promise for localized cancer therapeutic delivery to overcome the inefficiencies, toxicity, dosing issues and side-effects of systemic drug delivery in oncology applications.

Therapeutic: Drug Delivery; Infection control

Rick O’Connor CEO

Coming soon.

Therapeutic: Coming soon.

Allan Böhm Chief Executive & Medical Officer

Seerlinq (Slovakia, Bratislava) is the world’s first certified medical device enabling non-invasive, home-based monitoring of cardiac filling pressure—an essential parameter in managing heart failure. By detecting deterioration early, Seerlinq’s telemonitoring solution reduces heart failure hospitalizations by over 75%, addressing a global burden of more than 10 million admissions and $100 billion in annual healthcare costs.

Therapeutic: Remote Patient Monitoring; Heart Failure Diagnostics, Telemonitoring, Precision Medicine

Bart Bandy CEO

Solenic Medical, Inc. (Addison, Texas, USA) is clinical stage company pioneering a non-invasive solution for infected implants, like prosthetic knees and hips, utilizing alternating magnetic fields (AMF). This technology, designated a U.S. FDA Breakthrough Device, targets infections complicated by biofilms on implant surfaces. In-vitro and large animal studies demonstrated a significant bacteria reduction within safe temperature ranges. The solution targets safe and effective treatment for implant infections.

Therapeutic: Orthopedics-Spine; Infection Treatment

Mano Thubrikar President & Founder

Our Company developed the Optimum Transcatheter Aortic Valve and delivery catheter for aortic stenosis patients. Optimum TAV is a short, self-expanding valve with preclinical durability matching surgical valves. It avoids tissue damage from balloon-expansion and allows unrestricted coronary access. 12 patients implanted in Europe have great outcomes out to 3.5 years. Our FIH patient in Brazil is at 7 years post-implant. Increasingly, younger patients with current TAVR valves require Redo-TAVR. Optimum TAV could completely avoid or delay Redo-TAVR for years.

Therapetic: Interventional; Cardiovascular

Craig Misrach, President & CEO

UpLyft (San Diego, CA) is the first FDA registered independent and "zero-lifting" seated transfer system between bed and wheelchair for people with limited mobility. Dual controls can be operated by either the patient or healthcare worker, allowing for both self-transfer and assisted-transfer without any physical labor required.

Therapeutic: Orthopedics-Spine

Eli Bar CEO & Founder

Valfix Medical (Framingham, MA, USA) is developing a robotic-assisted transcatheter platform for treating severe functional mitral regurgitation (FMR). Our system is designed to perform a definitive, surgical-grade annuloplasty repair in a minimally-invasive procedure. This technology aims to restore heart function and halt disease progression for the millions of high-risk heart failure patients who are currently left with no effective treatment options.

Therapeutic: Cardiovascular; Robotics

Thomas Arnold CEO

ViCentra (The Netherlands - Utrecht) is transforming diabetes care with Kaleido, the smallest and lightest insulin patch pump system in its class. It’s a next-generation insulin pump system engineered for today’s users and tomorrow’s healthcare models. Kaleido delivers premium, flexible, and human-first diabetes technology designed to outperform outdated, one-size-fits-all solutions with a seamless blend of performance, lifestyle integration, and user satisfaction.

Therapeutic: Diabetes management; Insulin delivery system; Medical devices – Continuous Subcutaneous Insulin Infusion (CSII) systems

Hannah Zhang CEO

Zepto Life Technology (St. Paul, Minnesota, United States) has developed the first rapid liquid-biopsy platform for infectious diseases, starting with invasive fungal infections. Hospitals still rely on cultures that take days; during that wait, patients deteriorate and treatment costs rise. Our sample-to-result magnetic-sensor platform detects 20+ fungal species directly from blood and delivers species-level answers in minutes, enabling targeted therapy sooner and saving lives. Fungal infections are responsible for 3.7 million deaths worldwide each year, underscoring the urgent need for faster diagnosis. Based in St. Paul, Minnesota.

Therapeutic: Diagnostics